Sarepta Therapeutics, Inc. SRPT Loans Payable, Noncurrent
Loans Payable, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermLoansPayable.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s loans payable, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s loans payable, noncurrent?
- Sarepta Therapeutics, Inc. (SRPT) reported loans payable, noncurrent of $838.16M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s loans payable, noncurrent changed year-over-year?
- Sarepta Therapeutics, Inc.'s loans payable, noncurrent decreased by 26.4% year-over-year, from $1.14B to $838.16M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s loans payable, noncurrent?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s loans payable, noncurrent has grown at a -3.5% compound annual growth rate (CAGR), from $992.49M to $828.97M.
- What does loans payable, noncurrent mean?
- This represents the portion of debt obligations that are due beyond the next twelve months, excluding standard notes or bonds payable. It captures long-term financing arrangements that impact the company's overall leverage and interest expense profile. Tracking this metric is essential for evaluating the company's long-term solvency and its reliance on external debt financing for capital structure management.